Russian Heart Failure Journal 2015year Treatment of arterial hypertension and chronic heart failure in patients with pronounced myocardial hypertrophy without left ventricular outflow tract obstruction


To access this material please log in or register

Register Authorize
2015/№3

Treatment of arterial hypertension and chronic heart failure in patients with pronounced myocardial hypertrophy without left ventricular outflow tract obstruction

Demkina A. E.1, Khashieva F. M.1, Krylova N. S.1, Kovalevskaya E. A.2, Poteshkina N. G.1
1 – State Budgetary Educational Institution of Higher Professional Education, “N.I. Pirogov Russian National Research Medical University” of the RF Ministry of Health Care, Ostrovityanova 1, Moscow 117997
2 – State Budgetary Institution of Health Care, “Municipal Clinical Hospital #52 of the Moscow Department of Health Care”, Pekhotnaya 3, Moscow 123182

Keywords: hypertrophic cardiomyopathy, ACE inhibitors, perindopril, ventricular systolic and diastolic function

DOI: 10.18087/rhfj.2015.3.2013

Background. In patients of older age groups, arterial hypertension (AH) in combination with CHF symptoms associated with hypertrophic cardiomyopathy (HCMP) creates conditions, when monotherapy with recommended drugs is insufficient to achieve target BP and improve clinical status of the patients. Aim. To study efficacy of the ACE inhibitor, perindopril, as a part of beta-blocker (BB) based combination therapy in patients with nonobstructive HCMP (NHCMP) and AH. Materials and methods. 29 patients with NHCMP and AH (20 females, mean age 59.2±14.0) were evaluated. Patients were randomized to two groups: group 1 included 9 patients (5 females; mean age 52.6±18.0) receiving bisoprolol 6.2±3.0 mg; group 2 consisted of 20 patients (15 females, mean age 62.5±10.5) receiving perindopril 3.7±1.4 mg in addition to bisoprolol 5.0±1.0 mg. The study involved evaluation of patients’ clinical status using the Minnesota Living with Chronic Heart Failure (CHF) Questionnaire (MLHFQ); the Clinical Condition Scale (CCS) for CHF patients; measurement of plasma brain natriuretic peptide (BNP); 24‑h BP monitoring (24h-BPM); and EchoCG with tissue Doppler imaging (TDI). The study was performed after randomization and after 6‑month follow-up. Results. In an intragroup comparison after 6 months of treatment, patients of group 2 showed significant decreases in CHF NYHA functional class (р=0.02), CCS score (р=0.005), BNP level (р=0.003), mean systolic BP (mSBP) (р=0.0006), mean diastolic BP (mDBP) (р=0.0001), isovolumetric relaxation time (IVRT) of transmitral flow (р=0.01), right ventricular Tei index (р=0.03), segmental ivrt’ of lateral mitral fibrous annulus (MFA) (р=0.01), and an increase in the s’ peak of lateral MFA (р=0.005) by TDI data. After the 6‑month follow-up, patients of group 1 showed a decrease in total CCS score (р=0.04) and an increase in BNP (р=0.04) without changes in parameters of EchoCG, TDI and 24h-BPM. After 6 months of therapy, an intergroup analysis showed that values of mSBP (р=0.02), right ventricular Tei index (р=0.03), and segmental ivrt’ (р=0.03) of lateral and septal MFA sites by TDI data were lower in group 2 than in group 1 while systolic peaks (s’) on lateral and septal MFA were higher than in group 1 (р=0.03). Conclusion. Addition of the ACE inhibitor, perindopril, to the BB treatment improved the clinical status, reduced BNP levels, improved diastolic and systolic function of both ventricles and reduced BP in patients with NHCMP in combination with AH.
  1. Рабочая группа по лечению артериальной гипертонии Европейского Общества Гипертонии (European Society of Hypertension, ESH) и Европейского Общества Кардиологов (European Society of Cardiology, ESC). Рекомендации по лечению артериальной гипертонии ESH / ESC 2013. Российский кардиологический журнал. 105 (1):7–94.
  2. Якушин С. С., Филиппов Е. В. Гипертрофическая кардиомиопатия: основы диагностики и лечения. Клиницист. 2007 (3):7–14.
  3. Kato T. S., Noda A., Izawa H., Yamada A., Obata K., Nagata K., et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. Circulation. 2004;110 (25):3808–3814.
  4. Караулова Ю. Л., Павлова А. В., Моисеев В. С., Кобалава Ж. Д. Изучение клинико- генетических детерминант гипертрофии левого желудочка у больных артериальной гипертонией и гипертрофической кардиомиопатией. Практикующий врач сегодня. 2006 (1):5–9.
  5. Хабарова Н. В. Оценка эффективности дифференцированного лечения ГКМП на основе длительного проспективного наблюдения. – Москва, 1994. – 148 с.
  6. Гуревич М. А. Принципы консервативной терапии гипертрофической кардиомиопатии. Consilium Medicum. 2001;10 (1):497–499.
  7. Penicka M., Gregor P., Kerekes R ., Marek D., Curila K., Krupicka J., et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn. 2009;11 (1):35–41.
  8. Araujo A. Q., Arteaga E., Ianni B. M., Buck P. C., Rabello R ., Mady C. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005;96 (11):1563–1567.
  9. Topol E. J., Traill T. A., Fortuin N. J. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312 (5):277–283.
  10. Varma P. K., Neema P. K. Hypertrophic cardiomyopathy: part 1 – introduction, pathology and pathophysiology. Ann Card Anaesth. 2014;17 (2):118–124.
  11. Malik R ., Maron M. S., Rastegar H., Pandian N. G. Hypertrophic Cardiomyopathy with Right Ventricular Outflow Tract and Left Ventricular Intracavitary Obstruction. Echocardiography. 2014;31 (5):682–685.
  12. Finocchiaro G., Knowles J. W., Pavlovic A., Perez M., Magavern E., Sinagra G., et al. Prevalence and clinical correlates of right ventricular dysfunction in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014;113 (2):361–367.
  13. Богданов Д. В. Ремоделирование правого желудочка при гипертрофической необструктивной кардиомиопатии. Журнал Сердечная Недостаточность. 2009;10 (5):263–265.
  14. Васюк Ю. А., Хадзегова А. Б., Иванова С. В., Ющук Е. Н., Амирбигешвили И. М., Матвеева О. С., Шупенина Е. Ю., Хучинаева А. М., Надина Е. В., Синицына И. А., Садулаева И. А. Возможности использования индекса производительности миокарда левого и правого желудочков (Tei – индекс) в оценке эффективности лечения артериальной гипертензии. Журнал Сердечная Недостаточность.;13 (3):162–166.
  15. Флакскампф Ф. А. Практическая эхокардиография. (+CD) Руководство по эхокардиографической диагностике. – Москва. МЕДпресс-информ, 2013. – 872 с.
Demkina A. E., Khashieva F. M., Krylova N. S., Kovalevskaya E. A., Poteshkina N. G. Treatment of arterial hypertension and chronic heart failure in patients with pronounced myocardial hypertrophy without left ventricular outflow tract obstruction. Russian Heart Failure Journal. 2015;16 (3):153–160

To access this material please log in or register

Register Authorize
Ru En